Literature DB >> 32924719

Population Trends in All-Cause Mortality and Cause Specific-Death With Incident Atrial Fibrillation.

Sheldon M Singh1,2, Husam Abdel-Qadir2,3,4,5, Andrea Pang3, Jiming Fang3, Maria Koh3, Paul Dorian2,6, Harindra C Wijeysundera1,2,3,4, Dennis T Ko1,2,3,4.   

Abstract

BACKGROUND Limited studies have evaluated population-level temporal trends in mortality and cause of death in patients with contemporary managed atrial fibrillation. This study reports the temporal trends in 1-year overall and cause-specific mortality in patients with incident atrial fibrillation. METHODS AND RESULTS Patients with incident atrial fibrillation presenting to an emergency department or hospitalized in Ontario, Canada, were identified in population-level linked administrative databases that included data on vital statistics and cause of death. Temporal trends in 1-year all-cause and cause-specific mortality was determined for individuals identified between April 1, 2007 (fiscal year [FY] 2007) and March 31, 2016 (FY 2015). The study cohort consisted of 110 302 individuals, 69±15 years of age with a median congestive heart failure, hypertension, age (≥75 years), diabetes mellitus, stroke (2 points), vascular disease, age (≥65 years), sex category (female) score of 2.8. There was no significant decline in the adjusted 1-year all-cause mortality between the first and last years of the study period (adjusted mortality: FY 2007, 8.0%; FY 2015, 7.8%; P for trend=0.68). Noncardiovascular death accounted for 61% of all deaths; the adjusted 1-year noncardiovascular mortality rate rose from 4.5% in FY 2007 to 5.2% in FY 2015 (P for trend=0.007). In contrast, the 1-year cardiovascular mortality rate decreased from 3.5% in FY 2007 to 2.6% in FY 2015 (P for trend=0.01). CONCLUSIONS Overall 1-year all-cause mortality in individuals with incident atrial fibrillation has not improved despite a significant reduction in the rate of cardiovascular death. These findings highlight the importance of recognizing and managing concomitant noncardiovascular conditions in patients with atrial fibrillation.

Entities:  

Keywords:  atrial fibrillation; cause of death; mortality

Year:  2020        PMID: 32924719     DOI: 10.1161/JAHA.120.016810

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   5.501


  7 in total

1.  Association between serum apolipoprotein B and atrial fibrillation: a case-control study.

Authors:  Xia Zhong; Huachen Jiao; Dongsheng Zhao; Jing Teng
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

2.  Atrial fibrillation in Mexican population: Differences in presentation, comorbidities and risk factors between men and women

Authors:  Humberto Rodríguez-Reyes; César I Laguna-Muñoz; Carlos F Gallegos-de Luna; Manuel O de-Los-Ríos-Ibarra; José L Salas-Pacheco; José L Leyva-Pons; Luz M Muñoz-Gutiérrez; Arturo Vargas-Hernandez; Karla M Rodríguez-Muñoz; Jaime Barragán-Luna; Marco A Alcocer-Gamba; Jorge Cortez-Lawrenz; Julio Farjat-Ruiz
Journal:  Arch Cardiol Mex       Date:  2022-07-01

3.  PRRX1 Loss-of-Function Mutations Underlying Familial Atrial Fibrillation.

Authors:  Xiao-Juan Guo; Xing-Biao Qiu; Jun Wang; Yu-Han Guo; Chen-Xi Yang; Li Li; Ri-Feng Gao; Zun-Ping Ke; Ruo-Min Di; Yu-Min Sun; Ying-Jia Xu; Yi-Qing Yang
Journal:  J Am Heart Assoc       Date:  2021-11-30       Impact factor: 6.106

4.  Association of Neighborhood-Level Material Deprivation With Atrial Fibrillation Care in a Single-Payer Health Care System: A Population-Based Cohort Study.

Authors:  Husam Abdel-Qadir; Leo E Akioyamen; Jiming Fang; Andrea Pang; Andrew C T Ha; Cynthia A Jackevicius; David A Alter; Peter C Austin; Clare L Atzema; R Sacha Bhatia; Gillian L Booth; Sharon Johnston; Irfan Dhalla; Moira K Kapral; Harlan M Krumholz; Candace D McNaughton; Idan Roifman; Karen Tu; Jacob A Udell; Harindra C Wijeysundera; Dennis T Ko; Michael J Schull; Douglas S Lee
Journal:  Circulation       Date:  2022-06-09       Impact factor: 39.918

5.  Association between Acid-Suppressive Drugs and Clinical Outcomes in Patients with Nonvalvular Atrial Fibrillation.

Authors:  Hideki Arai; Shinichiro Ueda; Kazutaka Uchida; Fumihiro Sakakibara; Norito Kinjo; Mari Nezu; Takeshi Morimoto
Journal:  Drugs R D       Date:  2022-07-19

6.  Surveillance for Outcomes Selected as Atrial Fibrillation Quality Indicators in Canada: 10-Year Trends in Stroke, Major Bleeding, and Heart Failure.

Authors:  Stephen B Wilton; Padma Kaul; Sunjidatul Islam; Clare L Atzema; Jennifer Cruz; Kendra MacFarlane; Robert McKelvie; Stephanie Poon; Laurie Lambert; Kathy Rush; Marc Deyell; D George Wyse; Jafna L Cox; Allan Skanes; Roopinder K Sandhu
Journal:  CJC Open       Date:  2021-01-13

7.  Use and Prescription of Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Multidisciplinary Consensus Document.

Authors:  Marco Proietti; Marina Camera; Maurizio Gallieni; Luigi Gianturco; Antonio Gidaro; Carlo Piemontese; Giuseppe Pizzetti; Franco Redaelli; Barbara Scimeca; Carlo Sebastiano Tadeo; Matteo Cesari; Giuseppe Bellelli; Laura Adelaide Dalla Vecchia
Journal:  J Pers Med       Date:  2022-03-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.